Nasdaq (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 18, 2017.
The following 54 securities will be added to the Index:
| Exchange | SYMBOL | COMPANY NAME |
| Nasdaq | ABUS | Arbutus Biopharma Cp |
| Nasdaq | ACRS | Aclaris Therapeutics, Inc. |
| Nasdaq | ADAP | Adaptimmune Theraptcs plc |
| Nasdaq | AKAO | Achaogen, Inc. |
| Nasdaq | AKCA | Akcea Therapeutics, Inc. |
| Nasdaq | ANAB | AnaptysBio, Inc. |
| Nasdaq | ASND | Ascendis Pharma |
| Nasdaq | ATNX | Athenex, Inc. |
| Nasdaq | AUPH | Aurinia Pharmaceuticals |
| Nasdaq | AXON | Axovant Sciences Ltd |
| Nasdaq | BIVV | Bioverativ Inc. |
| Nasdaq | CALA | Calithera Biosciences Com |
| Nasdaq | CARA | Cara Therapeutics, Inc. |
| Nasdaq | CASC | Cascadian Therapeutics Inc |
| Nasdaq | CLLS | Cellectis S.A. |
| Nasdaq | CLXT | Calyxt, Inc. |
| Nasdaq | CMRX | Chimerix, Inc. |
| Nasdaq | CNCE | Concert Pharmaceuticals, Inc. |
| Nasdaq | CORI | Corium International |
| Nasdaq | CRBP | Corbus Pharma Hlds |
| Nasdaq | CRSP | CRISPR Therapeutics AG |
| Nasdaq | CRVS | Corvus Pharma |
| Nasdaq | CTMX | CytomX Therapeutics, Inc. |
| Nasdaq | DOVA | Dova Pharmaceuticals, Inc. |
| Nasdaq | ECYT | Endocyte, Inc. |
| Nasdaq | GLPG | Galapagos NV |
| Nasdaq | GLYC | GlycoMimetics, Inc. |
| Nasdaq | GTHX | G1 Therapeutics, Inc. |
| Nasdaq | IMGN | ImmunoGen, Inc. |
| Nasdaq | JNCE | Jounce Therapeutics, Inc. |
| Nasdaq | KALA | Kala Pharmaceuticals, Inc. |
| Nasdaq | KURA | Kura Oncology, Inc. |
| Nasdaq | MEDP | Medpace Holdings, Inc. |
| Nasdaq | MNKD | MannKind Corporation |
| Nasdaq | MRNS | Marinus Pharmaceuticals |
| Nasdaq | MRSN | Mersana Therapeutics |
| Nasdaq | MYOK | MyoKardia, Inc. St |
| Nasdaq | NBRV | Nabriva Therapeutics plc |
| Nasdaq | NEOS | Neos Therapeutics, Inc. |
| Nasdaq | PBYI | Puma Biotechnology |
| Nasdaq | PETQ | PetIQ, Inc. |
| Nasdaq | QURE | uniQure NV |
| Nasdaq | RARX | Ra Pharmaceuticals |
| Nasdaq | RETA | Reata Pharmaceuticals |
| Nasdaq | SBBP | Strongbridge Biopharma plc |
| Nasdaq | SNDX | Syndax Pharmaceuticals |
| Nasdaq | SNNA | Sienna Biopharmaceuticals |
| Nasdaq | SVRA | Savara Inc. |
| Nasdaq | TOCA | Tocagen Inc. |
| Nasdaq | TTPH | Tetraphase Pharmaceuticals, Inc |
| Nasdaq | TXMD | THERAPEUTICSMD INC |
| Nasdaq | VCYT | Veracyte Inc |
| Nasdaq | VTL | Vital Therapies, Inc. |
| Nasdaq | VYGR | Voyager Therapeutics |
The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).
As a result of the re-ranking, the following 15 securities will be removed from the Index:
| Exchange | SYMBOL | COMPANY NAME |
| Nasdaq | AQXP | Aquinox Pharmaceuticals, Inc. |
| Nasdaq | ARLZ | Aralez Pharmaceuticals Inc. |
| Nasdaq | CGEN | Compugen Ltd |
| Nasdaq | CLSD | Clearside Biomedical, Inc. |
| Nasdaq | IPXL | Impax Laboratories, Inc. |
| Nasdaq | MACK | Merrimack Pharmactl |
| Nasdaq | MLNT | Cempra Inc |
| Nasdaq | MNOV | Medicinova Inc |
| Nasdaq | OMED | OncoMed Pharmaceuticals, Inc. |
| Nasdaq | ONVO | Organovo Hldgs Inc |
| Nasdaq | OPHT | Ophthotech Corp |
| Nasdaq | OTIC | Otonomy, Inc. |
| Nasdaq | TRVN | Trevena, Inc. |
| Nasdaq | VSAR | Versartis, Inc. |
| Nasdaq | XBIT | XBiotech Inc. |
